ReviewEpilepsy research2016
Response to placebo in clinical epilepsy trials--Old ideas and new insights.
Review in Epilepsy research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- Trial
- Trial
- A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.Cannabis and cannabinoid research · 2021Trial
- Counterintuitive: reducing regression-to-the-mean worsens efficiency in simulated clinical trials.Seizure · 2026Article
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.Current issues in molecular biology · 2026Review
- Epilepsy and Placebo: A Literature Review.Neurologic clinics · 2026Review
- Inductive reasoning with large language models: A simulated randomized controlled trial for epilepsy.Epilepsy research · 2025Article
- Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy.Epilepsia · 2025Article
- Re-evaluating the placebo response in recent canine dietary epilepsy trials.BMC veterinary research · 2024Article
- An observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies.BMC neurology · 2024Observational
- Review
- Inductive reasoning with large language models: a simulated randomized controlled trial for epilepsy.medRxiv : the preprint server for health sciences · 2024Article
- The present and future of seizure detection, prediction, and forecasting with machine learning, including the future impact on clinical trials.Frontiers in neurology · 2024Review
- Quantifying and controlling the impact of regression to the mean on randomized controlled trials in epilepsy.Epilepsia · 2023Article
- Investigating the trends in patient-reported outcomes pre-treatment and implications to efficacy analyses: A post-hoc analysis of a cancer clinical trial.Contemporary clinical trials communications · 2022Article
- Article
- Assessing preoperative hope and expectations related to functional neurosurgery: a new questionnaire.BMC psychology · 2022Article
- Dogs as a Natural Animal Model of Epilepsy.Frontiers in veterinary science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Randomized placebo-controlled trials are a mainstay of modern clinical epilepsy research; the success or failure of innovative therapies depends on proving superiority to a placebo. Consequently, understanding what drives response to placebo (including the "placebo effect") may facilitate evaluation of new therapies. In this review, part one will explore observations about placebos specific to epilepsy, including the relatively higher placebo response in children, apparent increase in placebo response over the past several decades, geographic variation in placebo effect, relationship to baseline epilepsy characteristics, influence of nocebo on clinical trials, the possible increase in (SUDEP) in placebo arms of trials, and patterns that placebo responses appear to follow in individual patients. Part two will discuss the principal causes of placebo responses, including regression to the mean, anticipation, classical conditioning, the Hawthorne effect, expectations from symbols, and the natural history of disease. Included in part two will be a brief overview of recent advances using simulations from large datasets that have afforded new insights into causes of epilepsy-related placebo responses. In part three, new developments in study design will be explored, including sequential parallel comparison, two-way enriched design, time to pre-randomization, delayed start, and cohort reduction techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.